MINUTES OF MEETING - March 6-7 
24 
Dr. Zaitlin said Dr. Shepherd would like to study that portion of the 
Cauliflower Mosaic Virus genome which confers aphid transmissibility. 
Dr. Zaitlin said the Guidelines contain a prohibition against using 
aphid transmissible strains of Cauliflower Mosaic Virus as recombinant 
DNA vectors. Dr. Zaitlin said that this stricture against using aphid 
transmissible Cauliflower Mosaic Virus is inconsistent, as there is 
no similar prohibition for other viruses. 
Dr. Zaitlin said Dr. Shepherd also requests permission to insert that 
portion of the genome which confers aphid transmissibility into non- 
aphid transmissible strains. These experiments would increase the 
virulence or host-range of a pathogen. Dr. Zaitlin said that Cauli- 
flower Mosaic Virus has a very restricted host-range. It attacks 
certain members of the cabbage Family. In addition, the virus does 
not replicate in the aphid and thus does not persist in the aphid. 
He noted that insect-proof cages are used in these studies. 
It was agreed that this proposal would appear in a Federal Register 
announcement as a proposed major action (dealing with both the 
specific and the generic case) and be discussed at the June RAC 
meeting. 
H. Introduction of rat insulin gene into mouse embryos 
Dr. Bems summarized a proposal from Dr. Howard Goodman of the 
University of California, San Francisco. He said Dr. Goodman preposes 
to use ^ defective SV40 genome as a vector to introduce the genes for 
rat (or human) insulin (or growth hormone) into mouse embryonic cells. 
The vectoV will hopefully integrate and rat insulin will be expressed. 
Dr. Bems said the two cell stage embryos would then be transplanted 
into a pseudopregnant surrogate mother mouse. These embryos should 
develop into adult mice producing chemically distinguishable rat 
insulin. Dr. Bems said Dr. Goodman in his cover letter suggests 
that this type of experiment could be covered by Section III-C-7-(a) 
of the Guidelines. In the text of the proposal, however Section III- 
C-l-(b)-(2) is cited. After further discussion and consideration 
of these two sections of the Guidelines, a concensus developed among 
the Committee members that Section III-C-l-(b)-(2) covers this 
experiment. 
XVII. PROPOSAL TO REMOVE CDC CLASS 3 ORGANISMS FROM PROHIBITED EXPERIMENTS 
Noting that this proposal must be published in the Federal Register for 
comment, Dr. Gottesman presented a draft proposal to remove CDC Class 3 
organisms from Section I-D-l of the Guidelines. She said that a working 
group had been appointed to review the desirability and the possible 
mechanisms for removing Class 3 agents from the prohibited category. 
[ 59 ] 
